



WHO-ILAR COPCORD

Stage II International Education on Treatment of Autoimmune Diseases a One-day International Symposium

Dua Mutiara Ballroom,
JW MARRIOTT Hotel

Saturday, May 21, 2005, Jakarta, Indonesia

Breakthrough in the Treatment of Lupus Nephritis and RF+ Rheumatoid Arthritis

Achievements of Remission in 2-4 months,
Remission with Oral Drugs in 5.5-7.5 months,
Remission without Drug in 3.5-4.5 years.

Expert comment on SBP-5- IMNs Protocol:

Outcome is beyond expectation

John Darmawan, MD, PhD,

WHO Expert on the Rheumatic Diseases, Geneva, Switzerland.

SBP-5- IMNs protocol provides new hope for patients with
Lupus Nephritis and RF+ Rheumatoid Arthritis

Prof. Zhao Dongbao,

Changhai Hospital, Shanghai, China

SBP-5- IMNs protocol offers a new era in Lupus Nephritis
and RF+ Rheumatoid Arthritis treatment

Prof. Tran Ngoc An,

Bach mai Hospital, Hanoi, Vietnam

SBP-5- IMNs protocol is well tolerated and significant
breakthrough for patients with Lupus Nephritis and
RF+ Rheumatoid Arthritis treatment

Prof. Syed Atigul Haq,

Bangabandhu, Sheikh Mujib Medical University Shahbagh, Dhaka, Bangladesh.

SBP-5- IMNs protocol: an innovative new approach in
Lupus Nephritis and RF+ Rheumatoid
Arthritis treatment management

Prof. Fereydoun Davatchi,

Rheumatology Research Center, Shariati Hospital, Tehran, Iran.

SBP-5- IMNs protocol a very cost effective treatment
option in Lupus Nephritis and RF+ Rheumatoid
Arthritis treatment management

Prof. Johannes J Rasker,

University Twente, Enschede, The Netherlands.

Organizing Committee:

COPCORD COORDINATOR:

John Darmawan, M.D.
Jalan Seroja Dalam 7,
Semarang 50241, Indonesia
Phone: 62-24-8447-345 and
62-24-8316-496
Fax: 62-24-8310-028



INVITATION

INVITATION

WHO-ILAR COPCORD

**Stage II International Education on
Treatment of Autoimmune Diseases
a One-day International Symposium**

Dua Mutiara Ballroom,
JW MARRIOTT Hotel
Saturday, May 21, 2005, Jakarta, Indonesia

**Breakthrough in the Treatment of
Lupus Nephritis and RF+
Rheumatoid Arthritis**

Achievements of Remission in 2-4 months,
Remission with Oral Drugs in 5.5-7.5 months,
Remission without Drug in 3.5-4.5 years.



Dear Colleagues,

It is our pleasure to cordially invite you to share our experience of the breakthrough in the therapy of the Autoimmune Diseases. Remission without Drug after treatment of Lupus Nephritis and Rheumatoid Factor Positive Rheumatoid Arthritis (RF+ Rheumatoid Arthritis) will be highlighted. A panel of seasoned researchers from Asia and Europe will present the result of their clinical investigations.

In the history of the outcome of treatment of Lupus Nephritis and RF+ Rheumatoid Arthritis, never before has such almost miraculous outcome been achieved. These are after 2-4 months by intravenous infusion, remission with oral drugs after 5.5-7.5 months, remission without drugs after 3.5-4.5 years of treatment.

The follow up of this international symposium is the transfer of technology of the Stepdown Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants (SBP-6-IMNs).

Rheumatologists and medical practitioners with particular interest in the field are able to access the website communication at www.LupusArthritisIndonesia.org.

We hope to share these experiences with you before we fade away due to retirement.



Chairman
John Darmawan, MD, PhD
WHO-ILAR COPCORD Coordinator
Semarang



Chairman
Prof. Dr. A. Remy Nasution, SpPD-KR
Director, Indonesia Rheumatic Center
Jakarta



Final PROGRAM SYMPOSIUM

“WHO-ILAR COPCORD
Stage II Education on Treatment of Autoimmune Diseases,
a One-day International Symposium, Saturday, May 21, 2005,
Dua Mutiara Ballroom, JW Marriott Hotel, Jakarta, Indonesia”

Breakthrough in the Treatment of Lupus Nephritis and RF+ Rheumatoid Arthritis -Achievements of Remission with Intravenous Therapy after 2-4 months, Remission with Oral Drugs after 5.5-7.5 months, and Remission without Drug after 3.5-4.5 years of treatment.

09.00-09.05	WELCOME SPEECH	By Prof. Dr. A. Remy Nasution, SpPD-KR President of the WHO-ILAR Stage II Education on Treatment of Autoimmune Diseases.
09.05-09.15	OPENING	By the Minister of Health *** Republic of Indonesia
Morning Session		
Breakthrough in the Treatment of Lupus Nephritis-Remission with Intravenous Therapy after 2-4 months		
Chairman : Co-Chairman:		Prof. Dr. A. Remy Nasution, SpPD-KR (Jakarta, Indonesia) Adi Wirawan Mardjuali MD, PhD, (Jakarta, Indonesia)
Review of the history of the Outcome of the Therapy of Lupus Nephritis John Darmawan, MD, PhD (Semarang, Indonesia)		
Outcome of Lupus Nephritis after Therapy with the SBP-5-IMNs Dr. Tran Thi Minh Hoa, (Hanoi, Vietnam)		
Seven-year Outcome of Lupus Nephritis after Treatment with the SBP-5-IMNs John Darmawan, MD, PhD (Semarang, Indonesia)		
Outcome of Lupus Nephritis after Treatment with the SBP-5-IMNs Prof. Zhao Dongbao (Shanghai, China)		
Randomized Controlled Trial: Outcome of Intravenous Cyclophosphamide and oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis Dato Dr Zaki Murad, (Kuala Lumpur, Malaysia)		
Summary John Darmawan, MD, PhD (Semarang, Indonesia)		
10.45-11.15	COFFEE BREAK	
Afternoon Session		
Breakthrough in the Treatment of RF+ Rheumatoid Arthritis - Remission under Intravenous Therapy after 2-4 months		
Chairman : Co-Chairman:		Prof. Johannes J Rasker, Enschede (The Netherlands) Adi Wirawan Mardjuali, MD, PhD (Indonesia)
Review of the history of the Outcome of treatment of RF+ Rheumatoid Arthritis Prof. Johannes J Rasker, Enschede (The Netherlands)		
Seven-years Outcome of RF+ Rheumatoid Arthritis After Treatment with the SBP-5-IMNs John Darmawan, MD, PhD (Semarang, Indonesia)		
Outcome of RF+ Rheumatoid Arthritis After Treatment with the SBP-5-IMNs Prof. Syed Atigul Haq (Dacca, Bangladesh)		
12.15-13.15	LUNCH BREAK	
Chairman : Co-Chairman:		John Darmawan, MD, PhD (Semarang, Indonesia) Prof. Zhao Dongbao (Shanghai, China)
Outcome of RF+ Rheumatoid Arthritis After Treatment with the SBP-5-IMNs Prof. Zhao Dongbao (Shanghai, China)		
Outcome of RF+ Rheumatoid Arthritis by the SBP-5-IMNs Dr. Soosan Soorosh (Teheran, Iran)		
Summary Prof. Johannes J Rasker, Enschede (The Netherlands)		
14.00-14.30	COFFEE BREAK	
14.30-15.45	PANEL DISCUSSION	Questions from the audience and Answers by the Panelists on The SBP-5-IMNs and SBP-6-IMNs in terms of efficacy, adverse effects, and cost-effectiveness. Panelists : John Darmawan, MD, PhD, Prof. Johannes J Rasker, and Prof. Dr. A. Remy Nasution, SpPD-KR, Prof. Zhao Dongbao, Prof. Syed Atigul Haq.
15.45-16.00	CLOSING	By the Protocol *** In confirmation